Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Balaglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 9/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.67 |
| ▸ | PPARA | Q07869 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | ESRRA | P11474 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Balaglitazone SCHEMBL20125574 | 1.00 | PPARG (1.00) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL29362039 | 1.00 | PPARG (1.00) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL20125575 | 1.00 | PPARG (1.00) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL6359086 | 0.99 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL2567773 | 0.99 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL2567779 | 0.99 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL5935613 | 0.99 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL5935616 | 0.99 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| SCHEMBL5844579 | 0.89 | PPARG (0.80) | PPARGFFAR1PPARAESRRA | |
| SCHEMBL1130955 | 0.88 | PPARG (0.79) | PPARGFFAR1PPARAESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 591 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377950-B2 | Crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt | DR. REDDY'S LABORATORIES LIMITED (IN) | 2013-02-19 | — | — | US | claimed |
| EP-1623984-B1 | Polymorphic form I of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2yl]methoxy]benzyl] thiazolidine-2,4-dione potassium salt | REDDYS LAB LTD DR (IN) | 2011-11-02 | — | — | EP | claimed |
| US-20110263630-A1 | SYNTHESIS OF METABOLICALLY STABLE AGENTS FOR ALCOHOL AND DRUG ABUSE | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2011-10-27 | — | — | US | claimed |
| US-20110092524-A1 | Agent for Enhancing Corneal Epithelial Barrier Function | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-04-21 | — | — | US | claimed |
| EP-2253325-A1 | AGENT FOR ENHANCING CORNEAL EPITHELIAL BARRIER FUNCTION | Santen Pharmaceutical Co., Ltd (JP) | 2010-11-24 | — | — | EP | claimed |
| US-7439248-B1 | Pharmaceutical composition and the process for its preparation | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-10-21 | — | — | US | claimed |
| EP-1949908-A1 | Combined use of derivatives of GLP-1 analogs and PPAR ligands | NOVO NORDISK A/S (DK) | 2008-07-30 | — | — | EP | claimed |
| US-7348329-B2 | Therapeutic agent for keratoconjunctival disorder | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-03-25 | — | — | US | claimed |
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| US-20070287669-A1 | Combined Use of Derivatives of GLP-1 Analogs and PPAR Ligands | NOVO NORDISK A/S (DK) | 2007-12-13 | — | — | US | claimed |
| US-20020010187-A1 | Pharmaceutical composition and the process for its preparation | NOVO NORDISK A/S (DK) | 2002-01-24 | — | — | US | claimed |
| WO-2001091751-A1 | NEW PHARMACEUTICAL COMPOSITION AND THE PROCESS FOR ITS PREPARATION | NOVO NORDISK A/S (DK) | 2001-12-06 | — | — | WO | claimed |
| WO-2001089523-A1 | NEW PHARMACEUTICAL COMPOSITION AND THE PROCESS FOR ITS PREPARATION | NOVO NORDISK A/S (DK) | 2001-11-29 | — | — | WO | claimed |
| US-20010031759-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. | 2001-10-18 | — | — | US | claimed |
| EP-1114047-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF THIAZOLIDINE-2,4-DIONE DERIVATIVES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-07-11 | — | — | EP | claimed |
| WO-2001019830-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | claimed |
| WO-2001019831-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | claimed |
| WO-2001017516-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2001-03-15 | — | — | WO | claimed |
| WO-2000015638-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF THIAZOLIDINE-2,4-DIONE DERIVATIVES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-03-23 | — | — | WO | claimed |
| US-5985884-A | TREATMENT AND/OR PROPHYLAXIS OF DISEASES OR CONDITIONS IN WHICH INSULIN RESISTANCE IS THE UNDERLYING PATHOPHYSIOLOGICAL MECHANISM SUCH AS TYPE II DIABETES, IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDAEMIA, HYPERTENSION, CORONARY HEART DISEASE | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-11-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | PPM1B, PPM1D, PTPRS | PPARG 1818/4885FFAR1 2492/4885PPARA 2456/4885 |
| US-20110263630-A1 | SYNTHESIS OF METABOLICALLY STABLE AGENTS FOR ALCOHOL AND DRUG ABUSE | ADH1A, ADH1C, ADH5 | PPARG 367/4885FFAR1 245/4885PPARA 453/4885 |
| US-20020010187-A1 | Pharmaceutical composition and the process for its preparation | CYP3A5, CYP2C19, CYP3A4 | PPARG 966/4885FFAR1 3795/4885PPARA 1774/4885 |
| US-20010031759-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B1 | PPARG 380/4885FFAR1 1277/4885PPARA 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.